Stem cell therapy in ophthalmology for MS opthalmology theory exam

Reading File

Finding Sources

Searching PubMed

stem cell therapy ophthalmology

Searching the Web

stem cell therapy in ophthalmology exam notes limbal stem cell deficiency retinal

Finding Sources

Reading File

Stem Cell Therapy in Ophthalmology

1. Introduction

Stem cells are undifferentiated cells capable of self-renewal and differentiation into specialized cell types. In ophthalmology, they have moved from "adjunct/experimental" to standard-of-care in ocular surface disease and are in advanced clinical trials for retinal disease. Exam relevance centers on limbal stem cells (cornea) and retinal/RPE stem cells, with mesenchymal stem cells (MSCs) for immunomodulation.

2. Types of Stem Cells Used

Type	Source	Main ophthalmic use
Limbal epithelial stem cells (LESCs)	Palisades of Vogt (limbus)	Corneal surface reconstruction
Embryonic stem cells (ESCs)	Blastocyst	RPE/photoreceptor replacement (AMD)
Induced pluripotent stem cells (iPSCs)	Reprogrammed somatic cells	Autologous RPE sheets, disease modeling
Mesenchymal stem cells (MSCs)	Bone marrow, adipose, umbilical cord	Uveitis, optic neuropathy, immunomodulation
Oral mucosal epithelial cells	Buccal mucosa	Alternative to limbal graft (COMET)
Conjunctival/Muller glia-derived progenitors	Retina	Experimental retinal regeneration

3. Ocular Surface — Limbal Stem Cell Deficiency (LSCD)

This is the best-established clinical application and the most commonly asked topic.

Etiology

Acquired: chemical/thermal burns, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, chronic contact lens wear, multiple surgeries, aniridia-related keratopathy, chronic limbitis
Inherited: aniridia, ectodermal dysplasia

Clinical features: conjunctivalization of cornea, persistent epithelial defects, corneal neovascularization, loss of Palisades of Vogt, irregular epithelium, chronic pain/photophobia. Diagnosis confirmed by impression cytology (goblet cells on cornea) - Kanski's Clinical Ophthalmology, p. 5355 area.

Management ladder

Conservative: preservative-free lubricants, punctal occlusion, autologous serum eye drops (20% q.i.d.), bandage contact lens, short-course topical steroids - The Wills Eye Manual
Surgical debridement for partial LSCD
Stem-cell-based surgery for total/complete LSCD:
- CLAU (Conjunctival Limbal Autograft) - from healthy fellow eye, unilateral disease
- CLAL (Conjunctival Limbal Allograft) - living-related or cadaveric donor, bilateral disease (needs systemic immunosuppression)
- KLAL (Keratolimbal Allograft) - cadaveric, larger limbal tissue
- CLET (Cultivated Limbal Epithelial Transplantation) - small limbal biopsy expanded ex vivo on amniotic membrane/fibrin, then transplanted; the only cell-based therapy formally approved (EU, as "Holoclar")
- SLET (Simple Limbal Epithelial Transplantation) - Sangwan et al. (2012), Indian innovation; small limbal biopsy pieces distributed directly onto amniotic membrane over the cornea in situ, no ex vivo culture needed - cheap, single-stage, widely used in India, high-yield exam topic
- COMET (Cultivated Oral Mucosal Epithelial Transplantation) - autologous, avoids immunosuppression, used in bilateral total LSCD
If stem cell therapy fails or ocular surface is too hostile: keratoprosthesis (Boston KPro type I/II, MOOKP)

Global Consensus (Cornea, 2020) grades LSCD as partial/total and unilateral/bilateral, guiding the choice among the above.

4. Retina — Stem Cell Applications

Age-related macular degeneration (AMD)

RPE is lost early in dry AMD/geographic atrophy; strategy is RPE cell replacement using hESC- or iPSC-derived RPE, delivered as cell suspension or pre-formed monolayer sheets on a scaffold
Aim: rescue photoreceptors by restoring RPE support (phagocytosis of outer segments, visual cycle, growth factor secretion) rather than direct vision restoration
Early-phase trials show safety and graft survival; functional visual gains remain modest

Retinitis pigmentosa / inherited retinal dystrophies

Photoreceptor precursor cell transplantation and retinal progenitor cell injections are being trialed; a 2023 systematic review/meta-analysis (PMID 37798796) found stem cell therapy for inherited retinal disease shows favorable safety with variable/modest visual acuity benefit - evidence still preliminary.

Uveitis

MSCs and MSC-derived extracellular vesicles are being explored for their immunomodulatory (not regenerative) effect - suppressing T-cell activation and pro-inflammatory cytokines. A 2024 systematic review of preclinical studies (PMID 38600361, Eye) supports efficacy signals in animal models but notes lack of human trial data.

Glaucoma

Experimental work on trabecular meshwork stem/progenitor cells to restore outflow function - still preclinical.

Optic neuropathy

MSC and neural stem cell approaches for retinal ganglion cell/optic nerve protection - largely animal-model stage.

5. Advantages vs Limitations

Advantages: restores anatomically appropriate, self-renewing tissue; SLET/CLET avoid large donor tissue harvest; autologous options (SLET, COMET, iPSC-RPE) avoid lifelong immunosuppression.

Limitations/challenges

Immune rejection with allogeneic grafts (CLAL, KLAL, allogeneic hESC-RPE)
Tumorigenic risk with pluripotent stem cells (ESC/iPSC) - teratoma risk
Ethical concerns with embryonic stem cells
Limited long-term functional (visual acuity) data for retinal trials
Success depends on ocular surface milieu - dry eye, symblepharon, and limbal niche health affect graft take
High cost and limited availability of cell-culture facilities for CLET

6. Recent Evidence Check

Recent systematic reviews/meta-analyses (last ~2-3 years) largely support the library textbook framework but add nuance:

Inherited retinal disease stem cell therapy: safety established, efficacy modest (PMID 37798796)
MSC therapy for uveitis: promising in preclinical models only, human data still lacking (PMID 38600361)

These don't contradict standard teaching but confirm that retinal/uveitis stem cell therapy remains investigational, while corneal (limbal) stem cell therapy is the only clinically mature, exam-testable "real world" application (CLET approved in EU; SLET widely practiced).

PASCAL (Pattern Scan Laser) Therapy — Short Note for MS Ophthalmology Theory

(Note: I found no dedicated textbook chapter on PASCAL in the library's indexed ophthalmology texts — Kanski's and Wills Eye Manual cover conventional laser photocoagulation principles but not PASCAL by name. The note below is compiled from PubMed literature and standard retina references — treat it as supplementary, cross-check with your retina course text.)

1. Definition

PASCAL = Pattern Scan Laser, a semi-automated diode-pumped, frequency-doubled Nd:YAG (532 nm) photocoagulator (OptiMedica, later Topcon/Iridex) that delivers pre-set geometric patterns of laser spots (grids, arcs, rings) in rapid succession using very short pulse durations (10-20 ms) compared to conventional single-spot lasers (100-200 ms).

2. Basic Laser-Tissue Dosimetry Equation

The energy delivered to tissue by any photocoagulator follows:

E = P × t

where:

E = energy delivered (Joules)
P = laser power (Watts)
t = pulse duration (seconds)

Because PASCAL shortens t by roughly 5-10 fold (20 ms vs 100-200 ms conventional), an equivalent burn intensity requires proportionally higher P, since the energy density needed for a visible retinal burn (grade II-III) is comparatively fixed:

P(PASCAL) ≈ P(conventional) × [t(conventional) / t(PASCAL)]

In practice this is not a strict linear multiplier because of thermal confinement — with pulses shorter than the tissue's thermal relaxation time (~1-10 ms for a 100-500 micron spot at the RPE), heat has less time to diffuse laterally/axially before the pulse ends, so the burn stays more localized and less power increase is needed than the pure ratio predicts. Clinically, PASCAL settings typically use 2-3 times the power of a conventional 100 ms burn to achieve a similar visible endpoint at 20 ms.

3. Why Short Pulse Duration Works — Thermal Relaxation Time (TRT) Concept

TRT = time required for heat generated at the target to dissipate to ~50% of peak temperature
Conventional lasers (100-200 ms) exceed TRT → heat spreads beyond the intended spot → deeper, wider, more painful burns with greater collateral damage to inner retina and choroid
PASCAL's 10-20 ms pulses approach or stay near TRT → confines thermal damage to the RPE/outer retina, sparing the neurosensory retina and reducing pain, scarring, and choroidal damage

4. Technique / How It Works

Slit-lamp or endolaser delivery system with a scanning mirror
Operator pre-selects a pattern (e.g., 4x4 grid array of 25-100+ spots) and spot spacing
A single foot-pedal depression fires the entire pattern in <1 second (pattern delivered spot-by-spot at 10-20 ms per spot, total pattern time often under 0.5-0.7 sec)
Reduces number of individual pedal activations from thousands (conventional PRP) to a handful

5. Clinical Applications

Indication	Use
Panretinal photocoagulation (PRP) in proliferative diabetic retinopathy	Primary use — single/fewer sessions vs multi-session conventional PRP
Focal/grid laser for diabetic macular edema	Precise, evenly-spaced spots
Retinal breaks/tears, lattice degeneration	Barrage laser
Laser iridotomy (with 532 nm/combined Nd:YAG)	Reduced endothelial cell loss vs conventional (Kim et al., PMC4413573)
Pattern scanning laser trabeculoplasty (PSLT)	Newer glaucoma indication

6. Advantages over Conventional Argon/Diode PRP

Less pain — shorter pulse, less inner retinal/nerve fiber layer heating (well-documented in multiple RCTs, e.g., Manchester Pascal Study)
Faster procedure — pattern delivery vs single spots; full PRP achievable in 1-2 sessions vs 3-4
More precise, uniform, reproducible burns — computer-controlled spacing and grid geometry, less operator-dependent
Reduced collateral damage — smaller, shallower burns confined near RPE, less choroidal/inner retinal involvement, theoretically less risk of choroidal effusion and visual field loss
Less scarring/burn expansion over time — conventional burns tend to enlarge over months; PASCAL burns are more stable

7. Disadvantages / Limitations

Requires higher power settings, and if titration is inaccurate, risk of under- or over-treatment
Learning curve for power titration (test burn still required each session)
Equipment cost higher than conventional lasers
Long-term regression data for PDR initially less than conventional multi-session PRP in some trials (efficacy in inducing PDR regression essentially equivalent in meta-analyses, but ablation dosage/spot number needs to be higher than conventional to match efficacy — Manchester Pascal Study Report 4)
Some studies show comparable diabetic retinopathy regression to conventional laser only when adequate spot density/energy is used

8. Key Comparative Points (exam table)

Parameter	Conventional Laser	PASCAL
Pulse duration	100-200 ms	10-20 ms
Delivery	Single spot per pedal press	Pattern (multiple spots) per press
Pain	More	Less
Burn depth/spread	Deeper, less predictable	Shallow, more confined, uniform
Session number for PRP	3-4	1-2
Power required	Lower	Higher (2-3x)

9. One-line Definition to Memorize

"PASCAL is a pattern-scanning, short-pulse-duration (10-20 ms) photocoagulator that delivers multiple, uniformly spaced laser burns rapidly in preset geometric patterns, achieving thermally confined RPE-level burns with less pain and faster treatment compared to conventional single-spot lasers."

If your exam specifically wants a mathematical "equation" derivation (e.g., heat diffusion/Arrhenius damage equation used in laser-tissue interaction physics rather than the dosimetry ratio above), let me know and I can pull the biophysics (Beer-Lambert absorption + heat diffusion equation) used in laser-tissue interaction models.

This is a shared conversation. Sign in to Orris to start your own chat.